Longevity Patent Family

Application of target histone H4K77 acetylation modified substance in preparation of medicine for delaying immune aging, modified stem progenitor cell and application of modified stem progenitor cell

Source-linked patent metadata for Application of target histone H4K77 acetylation modified substance in preparation of medicine for delaying immune aging, modified stem progenitor cell and application of modified stem progenitor cell, including priority, record stage and longevity-topic connections.

Patent-family snapshot

Application publication visible

Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.

Representative publication
CN122005809A
Earliest priority
April 25, 2025
Latest publication
May 12, 2026
Family publications
1
Patent offices
1
Patent-to-Evidence Translation Map

What is happening in the same scientific field?

These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.

Organizations

Organizations named in this family

WEST CHINA HOSPITAL SICHUAN UNIVApplicant
Longevity context

Topics connected by metadata

Epigenetic alterations88% metadata match
Immune ageing88% metadata match
Knowledge connections

What this family cites

Earlier patent references
0
Scientific and other non-patent references
0
Priority dates represented
1

References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.

Technical classification

How the patent office classifies this invention

No patent classification is available in the retained record.

Verify in the original patent source →